Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System

Trends in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: 35(4), P. 258 - 265

Published: Jan. 21, 2025

Language: Английский

---

High-Intensity Interval Training Reduces Liver Enzyme Levels and Improves MASLD-Related Biomarkers in Overweight/Obese Girls

Nutrients, Journal Year: 2025, Volume and Issue: 17(1), P. 164 - 164

Published: Jan. 1, 2025

Background/Objectives: Despite the abundant body of evidence linking high-intensity interval training (HIIT) to cardiometabolic markers, little is known about how HIIT affects liver enzymes, particularly in obese adolescents. This study aimed investigate effects on metabolic dysfunction-associated steatotic disease (MASLD)-related biomarkers overweight/obese adolescent girls. Methods: Thirty-three girls (age, 17.0 ± 1.15 yr.; mass index, 33.3 4.77 kg/m2) were randomly assigned (n = 17) or control 16) groups. The group participated a nine-week program (three times weekly) without caloric restriction. Maximal aerobic speed, composition indexes, blood pressure, MASLD-related [liver enzymes (alanine aminotransferase (ALT) and aspartate (AST)), plasma lipids, uric acid, platelet count, homeostasis model assessment index for insulin-resistance (HOMA-IR)] examined at baseline after intervention. Results: Significant “time × group” interactions found systolic maximal ALT AST, glucose, HOMA-IR. resulted an increase speed (p 0.035) decrease lipids < 0.01), pressure 0.011), 0.013), AST 0.012), HOMA-IR but no significant changes acid count. None these markers changed group. Conclusions: improvement biomarkers. could be effective exercise therapy prevent reverse MASLD adolescents with obesity.

Language: Английский

---

Effects of Different Exercises Combined with Different Dietary Interventions on Body Composition: A Systematic Review and Network Meta-Analysis

Nutrients, Journal Year: 2024, Volume and Issue: 16(17), P. 3007 - 3007

Published: Sept. 5, 2024

Background: Exercise and dietary interventions are essential for maintaining weight reducing fat accumulation. With the growing popularity of various strategies, evidence suggests that combining exercise with offers greater benefits than either approach alone. Consequently, this combined strategy has become a preferred method many individuals aiming to maintain health. Calorie restriction, 5/2 intermittent fasting, time-restricted feeding, ketogenic diet among most popular today. Aerobic exercise, resistance training, mixed widely practiced forms physical activity. Exploring best combinations these approaches determine which yields effective results is both meaningful valuable. Despite trend, comparative analysis effects different lacking. This study uses network meta-analysis evaluate impact on body composition compare their efficacy. Methods: We systematically reviewed literature from database inception through May 2024, searching PubMed, Web Science, Embase, Cochrane Library. The was registered in PROSPERO under title: “Effects Combined Different Dietary Interventions Body Composition: A Systematic Review Network Meta-Analysis” (identifier: CRD42024542184). Studies were meticulously selected based specific inclusion exclusion criteria (The included studies must be randomized controlled trials involving healthy adults aged 18 65 years. Articles rigorously screened according specified criteria.), risk bias assessed using tool. Data aggregated analyzed meta-analysis, intervention efficacy ranked by Surface Under Cumulative Ranking (SUCRA) curves. Results: 78 5219 participants, comparing four interventions: calorie restriction (CR+EX), eating (TRF+EX), fasting (5/2F+EX), (KD+EX) composition. Intervention ranking as follows: (1) Weight Reduction: CR+EX > KD+EX TRF+EX 5/2F+EX (Relative CR+EX, effect sizes 5/2F+EX, 2.94 (−3.64, 9.52); 2.37 (−0.40, 5.15); 1.80 (−1.75, 5.34)). (2) BMI: 1.95 (−0.49, 4.39); 2.20 (1.08, 3.32); 1.23 (−0.26, 2.71)). (3) Fat Percentage: 2.66 (−1.56, 6.89); 2.84 (0.56, 5.13); 3.14 (0.52, 5.75).). (4) Lean Mass Male: −1.60 (−6.98, 3.78); −2.76 (−7.93, 2.40)). (5) Female: TRF+EX, −0.52 (−2.58, 1.55); −1.83 (−4.71, 1.04); −2.46 (−5.69,0.76).). Conclusion: emerged percentage while lean mass. For women, proved optimal preserving muscle While effectively reduces weight, it comparatively less at decreasing Hence, considered suboptimal.

Language: Английский

---

Nicotinamide Adenine Dinucleotide Phosphate Oxidases and Metabolic Dysfunction-Associated Steatotic Liver Disease

Antioxidants, Journal Year: 2025, Volume and Issue: 14(1), P. 83 - 83

Published: Jan. 13, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by lipid accumulation in the due to an excess their supplies or impairment management. While some patients remain stable for years, a proportion of them progress up steatohepatitis (MASH). MASLD links with systemic pathways being associated metabolic and non-metabolic diseases. Although represents first hit MASLD, pathophysiology its development progression MASH remains not completely understood. Oxidative stress has received particular attention recent as most oxidative process occurs liver, which also target stress-induced damage. Growing evidence linked activity nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) increased production reactive oxygen species damage fibrosis. NOX acts both hepatocytes non-parenchymal hepatic cells, contributing hepatocyte lipotoxicity, impaired microcirculation, stellate, mesenchymal stem cells activation proliferation. This review aims summarize current knowledge on involvement MASLD-MASH transition, focusing role isoforms, suggest targeting therapeutic approach MASLD.

Language: Английский

---

Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom

Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(3), P. 154 - 154

Published: Feb. 27, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic steatohepatitis (MASH), represent a growing global health problem linked to obesity, insulin resistance, dyslipidemia. MASLD often leads fibrosis, cirrhosis, hepatocellular carcinoma. Currently, therapeutic options are limited, emphasizing the need for novel, targeted pharmacological interventions. Resmetirom, selective thyroid hormone receptor beta (THR-β) agonist, offers promising approach by specifically enhancing hepatic metabolism while minimizing systemic effects. Clinical trials have demonstrated capacity reduce triglyceride accumulation improve lipid profiles. Early- advanced-phase studies, including MAESTRO program, highlight significant reductions in fat content favorable impacts on noninvasive biomarkers of fibrosis with minimal side This review highlights evidence from pivotal explores resmetirom's mechanism action, compares efficacy safety other emerging agents. While resmetirom marks breakthrough non-cirrhotic MASH management, further long-term studies essential fully evaluate clinical benefits potential regulatory approval broader use MASH.

Language: Английский

---

MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 855 - 855

Published: April 2, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic influenced by genetic, lifestyle, and environmental factors. While MASLD more prevalent in men, women are at increased risk after menopause, highlighting critical pathogenetic role of sex hormones. The complex interplay between estrogen deficiency, visceral fat accumulation, metabolic syndrome (MetS), inflammation accelerates progression, increases cardiovascular (CV) risk, triggers a cycle worsening adiposity, dysfunction, psychological problems, including eating disorders. Weight loss postmenopausal can significantly improve both outcomes, helping to prevent related conditions. This review examines prevalence MASLD, its comorbidities (type 2 diabetes T2D, CV, mental disorders), mechanisms, pharmacological treatment with GLP-1 receptor agonists (GLP1-RAs), focus on women. Given use GLP1-RAs obesity T2D patients, increase MetS this analyzes potential stable GLP-1–estrogen conjugate as therapeutic approach subgroup. By combining synergistic effects hormones, dual agonist has been shown food intake reward suppression, resulting greater weight improved insulin sensitivity, glucose, lipid metabolism. Therefore, we hypothesize that pharmacotherapy may provide targeted benefits than either hormone alone protecting liver, β-cells, overall health. As these only supported preclinical data, highlights need for future research evaluate confirm mechanisms efficacy clinical settings, particularly

Language: Английский

---

TJ0113 attenuates fibrosis in metabolic dysfunction-associated steatohepatitis by inducing mitophagy

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 156, P. 114678 - 114678

Published: April 18, 2025

Language: Английский

---

Enhanced accuracy and stability in automated intra-pancreatic fat deposition monitoring of type 2 diabetes mellitus using Dixon MRI and deep learning

Abdominal Radiology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Language: Английский

---

Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?

Current Opinion in Nephrology & Hypertension, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which also increasing, with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association. We present here a review associations possible interconnections between these two common processes. Epidemiological studies discordant regarding impact sex on association MASLD incident risk. The nature kidney stones rarely taken into account.A favorable milieu uric acid formation may be created by lower urine pH resulting from defective ammonium production insulin resistance, MASLD.Endogenous oxalate synthesis, major factor calcium stones, increased via decline activity enzymes involved detoxification glyoxylate, immediate precursor oxalate. driving remain to elucidated. Potential mechanisms identified underlying include an increase both stones.

Language: Английский

---

Efficacy of pemafibrate in metabolic dysfunction associated steatotic liver disease and metabolic dysfunction and alcohol associated steatotic liver disease with dyslipidemia: alanine aminotransferase reduction and predictive factors

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 3, 2025

Background: Although pemafibrate has shown promise in treating metabolic dysfunction associated steatotic liver disease (MASLD), reports on its effects and alcohol (MetALD) are limited. The aim of this study was to evaluate the efficacy pemafibrate both conditions complicated with dyslipidemia, focus alanine aminotransferase (ALT) reduction. Predictive factors for treatment response were also identified. Methods: This retrospective, single-center cohort included 96 patients MASLDand14 MetALD treated 24 weeks. Changes function tests, lipid profiles, body mass index analyzed. Factors predicting ALT reduction identified using correlation analysis multivariate regression. Patients categorized as responders or non-responders based changes at Results: After weeks, significant improvements observed tests profiles MASLD; similar benefits found MetALD. median rate -24.75%. Higher baseline aspartate (AST) gamma-glutamyl transferase (GGT) levels greater Baseline AST GGT above upper limit normal predictors Conclusions: Pemafibrate effectively improved MASLD by dyslipidemia. enzyme levels, particularly normal, treatment.

Language: Английский

---